Diarrhea-predominant irritable bowel syndrome （IBS-D） is a common digestive system disease with high prevalence and recurrence rates for years， high treatment costs， and serious impacts on patients' quality of life and economic burden. Therefore， it is important to explore new and safe treatment methods. The pathogenesis of IBS-D is complex， in which the gut-brain axis is a key factor. The gut-brain axis， a bidirectional signaling pathway connecting the gastrointestinal tract and the central nervous system， regulates gastrointestinal motility， secretion， and immune responses， playing a key role in the occurrence and development of IBS-D. Up to now， antidiarrheal agents， probiotics， and neurotransmitter modulators are the main methods for the clinical treatment of IBS-D. Although they can partially curb the progression of this disease， the therapeutic effects remain to be improved. Studies have confirmed that traditional Chinese medicine （TCM） has significant advantages in the treatment of IBS-D since it can regulate the gut-brain axis via multiple pathways and targets to improve the gastrointestinal motility and strengthen immune defenses. However， there is a lack of systematic reviews on the regulation of the gut-brain axis by TCM in the treatment of IBS-D. Based on the review of IBS-D-related articles published in recent years， this paper systematically summarized the relationship between the gut-brain axis and IBS-D and the role of TCM in the treatment， providing new ideas for the treatment of IBS-D.

Methamphetamine (METH) abuse is associated with significant neurotoxicity, high addiction potential, and behavioral abnormalities. Recent studies have identified a connection between the gut microbiota and METH-induced neurotoxicity and behavioral disorders. However, the underlying causal mechanisms linking the gut microbiota to METH pathophysiology remain largely unexplored. In this study, we employed fecal microbiota transplantation (FMT) and antibiotic (Abx) intervention to manipulate the gut microbiota in mice administered METH. Furthermore, we supplemented METH-treated mice with short-chain fatty acids (SCFAs) and pioglitazone (Pio) to determine the protective effects on gut microbiota metabolism. Finally, we assessed the underlying mechanisms of the gut-brain neural circuit in vagotomized mice. Our data provide compelling evidence that modulation of the gut microbiome through FMT or microbiome knockdown by Abx plays a crucial role in METH-induced neurotoxicity, behavioral disorders, gut microbiota disturbances, and intestinal barrier impairment. Furthermore, our findings highlight a novel prevention strategy for mitigating the risks to both the nervous and intestinal systems caused by METH, which involves supplementation with SCFAs or Pio.

China prospective multicenter birth cohort (Prospective Omics Health Atlas birth cohort, POHA birth cohort) study was officially launched in 2022. This study, in collaboration with 12 participating units, aims to establish a high-quality, multidimensional cohort comprising 20 000 naturally conceived families and assisted reproductive families. The study involves long-term follow-up of parents and offspring, with corresponding biological samples collected at key time points. Through multi-omics testing and analysis, the study aims to conduct multi-omics big data research across the entire maternal and infant life cycle. The goal is to identify new biomarkers for maternal and infant diseases and provide scientific evidence for risk prediction related to maternal diseases and neonatal health.

Hepatic fibrosis is a pathological process of chronic liver injury. Without timely intervention and treatment， liver fibrosis may eventually lead to liver cirrhosis and cancer. Janus kinase （JAK）/signal transducer and activator of transcription （STAT） signaling pathway is closely associated with the occurrence and development of liver fibrosis. Based on this， this paper summarized and analyzed the mechanism and effects of active ingredients and compounds of traditional Chinese medicine improving liver fibrosis based on JAK/STAT signaling pathway. It is found that the active ingredients and compounds of traditional Chinese medicine that promote blood circulation and remove blood stasis （ingredients such as ethanol extract of Euonymus alatus and paclitaxel， as well as compounds such as Ershiwuwei songshi pill and Ganfukang）， clear away heat and toxic material （ingredients such as betulinic acid， total flavonoids from Persicaria perfoliata， as well as compounds such as Pianzaihuang and Kehuang capsules）， and sooth the liver and promote qi circulation （ingredients such as fraxetin and cucurbitacin B， as well as compounds such as Chaihu shugan powder and Xiaochaihu decoction） can all relieve liver fibrosis by inhibiting the activity of the JAK/STAT signaling pathway， reducing inflammatory reactions， and inhibiting the proliferation of hepatic stellate cells.

Gastroesophageal reflux disease （GERD） is a gastrointestinal motility disorder characterized by the reflux of gastric contents into the esophagus， leading to symptoms such as acid reflux and heartburn. The incidence of GERD is closely associated with psychological disorders， including anxiety and depression. The brain-gut axis， serving as a mediator of the bidirectional connection between the brain and the gastrointestinal tract， plays a crucial role in the occurrence and development of GERD with anxiety and depression. Various therapeutic approaches， including compound Chinese medicine internal therapy （such as Pingchong jiangni decoction， Tiaozhong huashi decoction， etc.）， combination therapy of internal and external Chinese medicine （such as Lianzhi xiere decoction combined with acupoint application， acupuncture at the back segment of governor vessel plus Chinese medication of soothing the liver and gallbladder， etc.）， and combination therapy of internal Chinese and western medicine （including Jianpi shugan decoction combined with rabeprazole， rabeprazole combined with Jianzhong jiangni decoction， etc.）， have been shown to regulate brain-gut peptides， intestinal flora， inflammatory factors and gastrointestinal hormones， thereby effectively alleviating GERD symptoms， anxiety and depression， and enhancing patients’ quality of life.

Acute pancreatitis （AP） is one of the most clinically common acute digestive disorders characterized by quick onset，rapid progression，severe condition，and high mortality. If the disease is not timely intervened in the early stage，it can develop into severe AP in the later stage，which damages the long-term quality of life and brings serious economic burden to patients and their families. However， the pathogenesis of this disease is complex and has not been fully explained. The generation and development of AP is closely related to many signaling pathways. Among them，Toll-like receptor 4（TLR4），as a transmembrane signal transduction receptor，can mediate immune response and inflammatory response，and play a key role in the occurrence and development of AP. Traditional Chinese medicine（TCM）can regulate the TLR4 signaling pathway with multiple targets，multiple effects，and multiple administration methods to inhibit inflammatory response，and effectively intervene in the progression of AP， which has gradually become a new craze for preventing and treating AP. Many studies have shown that TCM has obvious advantages in the prevention and treatment of AP. It can effectively treat AP by regulating TLR4 signaling pathway，strengthening immune resistance and defense，and inhibiting inflammatory response. Despite of the research progress，there is still a lack of comprehensive review on TCM regulation of TLR4 signaling pathway in the treatment of AP. Therefore，the literature on TCM regulation of TLR4 signaling pathway published in recent years was systematically reviewed and elaborated，aiming to provide new ideas for the treatment of AP and further drug development.

Objective To evaluate the reporting quality of randomized controlled trials of TCM treatment of chronic obstructive pulmonary disease based on CONSORT statement and extended version and Jadad scale.To understand the current situation of TCM treatment of COPD RCT and provide reference for future research.Methods PubMed,Embase,Cochrane Controlled Trial Registry,Web of Science,China Journal Full Text Database(CNKI),Wanfang Data,VIP Chinese Journal Service Platform and SinoMed were searched.The retrieval time was from January 2012 to December 2022.CONSORT 2010 statement and extended version and Jadad scale were used to evaluate the quality of the included RCTS.Results A total of 291 literatures(279 Chinese,12 English)were included.In the evaluation of CONSORT declaration,73.47%and 34.69%of all items with reporting rate less than 50%in both English and Chinese respectively.In both English and Chinese,there were 25 and 9 items with reporting rates less than 10%,respectively.The difference in reporting rates of 17 items such as trial registration and outcome index was more than 50%.Evaluating TCM Formulas based on consor-Chm formulas,the reported rates of Chinese and English formulas were poor(<10%)in terms of TCM syndrome type and details of compound intervention measures.In evaluating acupuncture based on the STRICTA list,both Chinese and English reported low rates(<10%)in five aspects,including treatment site and number of needles used.The report rate of moxibustion method based on CONSORT extended version is generally good.According to SPSS25.0,there is a moderate correlation between CONSORT and Jadad(pearson0.419,P<0.01).Conclusion The report quality of TCM treatment of COPD RCTS needs to be further improved,and there are significant problems in text topic,key words,outcome index,blind method,trial registration and other aspects.In the follow-up research,multi-disciplinary talents should be involved and RCT research reports should be regulated strictly in accordance with CONSORT declaration and Jadad scale.This study provides some reference for improving the quality of RCT.

Objective To evaluate the reporting quality of randomized controlled trials of TCM treatment of chronic obstructive pulmonary disease based on CONSORT statement and extended version and Jadad scale.To understand the current situation of TCM treatment of COPD RCT and provide reference for future research.Methods PubMed,Embase,Cochrane Controlled Trial Registry,Web of Science,China Journal Full Text Database(CNKI),Wanfang Data,VIP Chinese Journal Service Platform and SinoMed were searched.The retrieval time was from January 2012 to December 2022.CONSORT 2010 statement and extended version and Jadad scale were used to evaluate the quality of the included RCTS.Results A total of 291 literatures(279 Chinese,12 English)were included.In the evaluation of CONSORT declaration,73.47%and 34.69%of all items with reporting rate less than 50%in both English and Chinese respectively.In both English and Chinese,there were 25 and 9 items with reporting rates less than 10%,respectively.The difference in reporting rates of 17 items such as trial registration and outcome index was more than 50%.Evaluating TCM Formulas based on consor-Chm formulas,the reported rates of Chinese and English formulas were poor(<10%)in terms of TCM syndrome type and details of compound intervention measures.In evaluating acupuncture based on the STRICTA list,both Chinese and English reported low rates(<10%)in five aspects,including treatment site and number of needles used.The report rate of moxibustion method based on CONSORT extended version is generally good.According to SPSS25.0,there is a moderate correlation between CONSORT and Jadad(pearson0.419,P<0.01).Conclusion The report quality of TCM treatment of COPD RCTS needs to be further improved,and there are significant problems in text topic,key words,outcome index,blind method,trial registration and other aspects.In the follow-up research,multi-disciplinary talents should be involved and RCT research reports should be regulated strictly in accordance with CONSORT declaration and Jadad scale.This study provides some reference for improving the quality of RCT.

Humans ; Cohort Studies ; Body Mass Index ; Percutaneous Coronary Intervention ; Coronary Artery Disease ; Inflammation ; Treatment Outcome ; Risk Factors